Enliven Therapeutics (ELVN) Other financing activities (2020 - 2026)
Enliven Therapeutics (ELVN) posted Other financing activities of $10.1 million for Q1 2026, up 1803.98% sequentially from $528000.0 in Q4 2025, and up 4196.15% YoY from $234000.0 in Q1 2025.
Enliven Therapeutics (ELVN) Other financing activities (2020 - 2026) Analysis & Trends
Enliven Therapeutics has reported Other financing activities for 7 years, with the latest figure at $10.1 million in Q1 2026.
- Quarterly Other financing activities rose 4196.15% year-over-year to $10.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $12.1 million (up 236.97% YoY) and the FY2025 annual result came in at $2.3 million, down 36.79% from the prior year.
- Other financing activities improved to $10.1 million in Q1 2026 per ELVN's latest filing, from $528000.0 in the prior quarter.
- Over five years, Other financing activities peaked at $10.1 million in Q1 2026 and troughed at $5000.0 in Q2 2022.
- A 5-year average of $1.1 million and a median of $252000.0 in 2024 frame the typical range for Other financing activities.
- The sharpest annual moves came in 2022 and 2026: Other financing activities sank 97.94% in 2022, then jumped 4196.15% in 2026.
- Over 5 years, Other financing activities stood at $13000.0 in 2022, then jumped by 592.31% to $90000.0 in 2023, then jumped by 403.33% to $453000.0 in 2024, then gained by 16.56% to $528000.0 in 2025, then jumped by 1803.98% to $10.1 million in 2026.
- According to Business Quant data, Other financing activities over the past three periods registered $10.1 million, $528000.0, and $209000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Enliven Therapeutics | 4.31 Bn | 3.41 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 29.59 Mn |
| Jun 30, 2026 | 29.59 Mn |
| Mar 31, 2026 | 10.05 Mn |
| Mar 31, 2026 | 10.05 Mn |
| Dec 31, 2025 | 528,000.00 |
| Dec 31, 2025 | 528,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Sep 30, 2025 | 209,000.00 |
| Jun 30, 2025 | 1.32 Mn |
| Jun 30, 2025 | 1.32 Mn |
| Mar 31, 2025 | 234,000.00 |
| Mar 31, 2025 | 234,000.00 |
| Dec 31, 2024 | 453,000.00 |
| Dec 31, 2024 | 453,000.00 |
| Sep 30, 2024 | 1.12 Mn |
| Sep 30, 2024 | 1.12 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Jun 30, 2024 | 1.79 Mn |
| Mar 31, 2024 | 270,000.00 |
| Mar 31, 2024 | 270,000.00 |